long intergenic non-protein coding RNA 1232Genealiases: LINC00449 · TCONS_00021520
Q-omics provides the consensus-scored LINC01232 profile across patient tissues and cancer cell-line models. LINC01232 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, LINC01232 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, LINC01232 RNA expression shows 18,802 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, BLCA, and ACC as cancer lineages where LINC01232 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01232 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01232 survival associations across molecular data types. LINC01232 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01232 RNA expression–survival associations across cancer types. High LINC01232 expression shows unfavorable associations in LIHC, KIRC, KIRP and HNSC, but favorable associations in SKCM and UCEC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for LINC01232 RNA expression.
This table summarizes LINC01232 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01232. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01232 shows lower tumor expression in THCA and higher tumor expression in BLCA, COAD, HNSC, KIRC and STAD. The BLCA box plot shows higher LINC01232 RNA expression in tumor versus normal tissue (log2 FC = +1.622, t-test p < 0.001).
This table shows molecular features associated with LINC01232 in patient tissues and cancer cell lines. In patient samples, LINC01232 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
